Last 13 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.08 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | 88.66 | — | 30.88 | 14.61 | 11.37 | — |
| — | — | — | — | — | — | — | +679.8% | — | — | — | — | — | |
| P/B Ratio | 0.00 | 0.00 | 1.26 | 1.91 | 0.91 | 0.57 | 0.39 | 1.54 | 0.96 | 3.82 | 3.40 | 1.08 | — |
| — | -99.9% | +222.0% | +23.8% | -5.6% | -85.1% | -88.5% | +42.5% | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 100.0% | — | -20.6% | 100.0% | 41.2% | 8.7% |
| — | — | — | — | — | — | — | +142.8% | — | -120.6% | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | -35470.4% | — | -2866.7% | -641.7% | -863.6% | -1375.8% |
| — | — | — | — | — | — | — | -4007.0% | — | +67.6% | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | -35093.2% | — | -2726.4% | -625.5% | -2575.3% | -2168.7% |
| — | — | — | — | — | — | — | -1262.7% | — | +79.5% | — | — | — |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.6% | -0.1% | -122.6% | -87.1% | -60.7% | -34.8% | -20.6% | -87.0% | -81.0% | -59.5% | -30.9% | -262.3% | — |
| — | +99.7% | -494.4% | -0.1% | +25.1% | +41.5% | +33.3% | +66.8% | — | — | — | — | — | |
| ROA | -0.4% | -0.1% | -67.0% | -58.6% | -46.3% | -27.9% | -14.8% | -52.9% | -52.5% | -38.9% | -22.4% | -57.2% | -38.3% |
| — | +99.7% | -353.1% | -10.7% | +11.8% | +28.3% | +34.1% | +7.5% | -36.9% | +31.0% | — | — | — | |
| ROIC | -0.8% | -0.2% | -120.9% | -125.4% | -137.8% | -116.3% | -142.3% | -105.8% | -107.5% | -99.4% | -78.1% | -60.2% | -66.2% |
| — | +99.9% | +15.0% | -18.5% | -28.2% | -17.0% | -82.2% | -75.8% | -62.5% | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 25.6% YoY to 2.83x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.35 | 0.26 | 0.11 | 0.10 | 0.08 | 0.42 | 0.19 | 0.30 | 0.18 | 0.14 | — |
| — | +13.9% | +337.0% | -38.1% | -42.2% | -67.9% | -55.6% | +205.5% | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.83 | 2.83 | 1.23 | 1.24 | 3.02 | 3.80 | 5.58 | 0.77 | 2.80 | 1.58 | 3.35 | 3.93 | 0.90 |
| — | -25.6% | -77.9% | +61.3% | +7.9% | +140.3% | +66.8% | -80.5% | +210.6% | -15.0% | — | — | — | |
| Quick Ratio | 2.83 | 2.83 | 1.23 | 1.24 | 3.02 | 3.80 | 5.58 | 0.77 | 2.80 | 1.58 | 3.35 | 3.93 | 0.90 |
| — | -25.6% | -77.9% | +61.3% | +7.9% | +140.3% | +66.8% | -80.5% | +210.6% | -15.0% | — | — | — | |
| Interest Coverage | -1445.45 | -6.08 | -7.44 | -6135.37 | -2397.71 | -433.74 | -760.64 | -1492.86 | -3236.61 | -2587.80 | -2808.07 | -19.50 | -17.35 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 13 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAzitra, Inc.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Azitra, Inc.'s business trajectory between earnings reports.